Thr505
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr505  -  NFkB-p65 (human)

Site Information
EAITRLVtGAQRPPD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 455490

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 3 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 , 2 , 3 ) , western blotting ( 1 , 2 , 3 )
Disease tissue studied:
bone cancer ( 2 , 3 )
Relevant cell line - cell type - tissue:
MEF (fibroblast) [NFkB-p65 (mouse), homozygous knockout] ( 1 ) , U2OS (bone cell) ( 2 , 3 )

Upstream Regulation
Regulatory protein:
ARF1 (human) ( 2 ) , ATR (human) ( 3 ) , p16-INK4A (human) ( 3 )
Putative in vivo kinases:
Chk1 (human) ( 3 )
Kinases, in vitro:
Chk1 (human) ( 3 )
Treatments:
caffeine ( 3 ) , cisplatin ( 1 , 2 ) , daunorubicin ( 2 ) , etoposide ( 2 ) , Go_6976 ( 2 , 3 ) , siRNA ( 3 ) , tamoxifen ( 3 ) , UV ( 2 )

Downstream Regulation
Effects of modification on biological processes:
apoptosis, inhibited ( 1 ) , cell growth, inhibited ( 1 ) , cell motility, inhibited ( 1 ) , cytoskeletal reorganization ( 1 ) , transcription, altered ( 1 ) , transcription, inhibited ( 3 )

References 

1

Msaki A, et al. (2011) The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration. Mol Biol Cell 22, 3032-40
21737676   Curated Info

2

Campbell KJ, Witty JM, Rocha S, Perkins ND (2006) Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-kappaB transactivation. Cancer Res 66, 929-35
16424027   Curated Info

3

Rocha S, et al. (2005) Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J 24, 1157-69
15775976   Curated Info